. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Toxicol Pathol. 2019 Nov 14;47(8):1004–1011. doi: 10.1177/0192623319878398

Table 1.

Silica enhances (↑) and DHA suppresses (↓) many inflammatory endpoints targeted by drugs either approved or in clinical trials for treatment of autoimmune disease.

Target	Silica	DHA	Treatment	Drug
IFNα	↑	↓	IFNα mAb	Rontalizumab, Sifalimumab⁵⁰
			IFNAR1 mAb	Anifrolumab⁵⁰
			IFNα vaccine	Interferon-α-kinoid (IFN-K)⁵⁰
BAFF	↑	↓	BAFF mAb	Belimumab (Benlysta™)⁵³
IL-6	↑	↓	IL-6R mAb	Tocilizumab⁵⁵
			IL-6 mAb	Sirukumab⁵⁶
			IL-6 mAb	Sirukumab⁵⁶
TNF-α	↑	↓	TNF-α mAb	Infliximab⁵⁷
MCP-1	↑	↓	Neutralize MCP-1	Emapticap⁵⁸
CD3	↑	↓	CD3 mAb	Muromonab-CD3⁵⁹